1	3	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Biofilms	_	_	NNS	_	_	_	_	_


1	As	_	_	IN	_	_	_	_	_
2	mentioned	_	_	VBN	_	_	_	_	_
3	above	_	_	RB	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	most	_	_	RBS	_	_	_	_	_
7	common	_	_	JJ	_	_	_	_	_
8	problems	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	stents	_	_	NNS	_	_	_	_	_
11	are	_	_	VBP	_	_	_	_	_
12	due	_	_	JJ	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	their	_	_	PRP$	_	_	_	_	_
15	clogging	_	_	VBG	_	_	_	_	_
16	due	_	_	JJ	_	_	_	_	_
17	to	_	_	TO	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	formation	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	biofilm	_	_	NN	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	adhesion	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	biological	_	_	JJ	_	_	_	_	_
26	substances	_	_	NNS	_	_	_	_	_
27	that	_	_	WDT	_	_	_	_	_
28	pass	_	_	VBP	_	_	_	_	_
29	through	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	stent	_	_	NN	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Biofilm	_	_	NNP	_	_	_	_	_
2	represents	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	most	_	_	RBS	_	_	_	_	_
5	widespread	_	_	JJ	_	_	_	_	_
6	way	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	microbial	_	_	JJ	_	_	_	_	_
9	growth	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	nature	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	critical	_	_	JJ	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	development	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	clinical	_	_	JJ	_	_	_	_	_
20	infections	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	produced	_	_	VBN	_	_	_	_	_
4	by	_	_	IN	_	_	_	_	_
5	bacteria	_	_	NN	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	host	_	_	NN	_	_	_	_	_
8	products	_	_	NNS	_	_	_	_	_
9	that	_	_	WDT	_	_	_	_	_
10	tend	_	_	VBP	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	adhere	_	_	VB	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	different	_	_	JJ	_	_	_	_	_
15	surfaces	_	_	NNS	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	create	_	_	VBP	_	_	_	_	_
3	huge	_	_	JJ	_	_	_	_	_
4	colonies	_	_	NNS	_	_	_	_	_
5	known	_	_	VBN	_	_	_	_	_
6	as	_	_	IN	_	_	_	_	_
7	biofilms	_	_	NNS	_	_	_	_	_
8	.	_	_	.	_	_	_	_	_


1	Existence	_	_	NN	_	_	_	_	_
2	in	_	_	IN	_	_	_	_	_
3	biofilms	_	_	NNS	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	them	_	_	PRP	_	_	_	_	_
7	more	_	_	RBR	_	_	_	_	_
8	advantageous	_	_	JJ	_	_	_	_	_
9	because	_	_	IN	_	_	_	_	_
10	biofilm	_	_	NN	_	_	_	_	_
11	provides	_	_	VBZ	_	_	_	_	_
12	protection	_	_	NN	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	their	_	_	PRP$	_	_	_	_	_
15	cells	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	maintains	_	_	VBZ	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	homeostasis	_	_	NN	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	and	_	_	CC	_	_	_	_	_
22	creates	_	_	VBZ	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	barrier	_	_	NN	_	_	_	_	_
25	that	_	_	WDT	_	_	_	_	_
26	isolates	_	_	VBZ	_	_	_	_	_
27	bacteria	_	_	NN	_	_	_	_	_
28	from	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	surroundings	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	extensive	_	_	JJ	_	_	_	_	_
4	communication	_	_	NN	_	_	_	_	_
5	between	_	_	IN	_	_	_	_	_
6	bacteria	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	effective	_	_	JJ	_	_	_	_	_
10	horizontal	_	_	JJ	_	_	_	_	_
11	transfer	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	resistance	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	virulence	_	_	NN	_	_	_	_	_
16	genes	_	_	NNS	_	_	_	_	_
17	that	_	_	WDT	_	_	_	_	_
18	make	_	_	VBP	_	_	_	_	_
19	bacteria	_	_	NN	_	_	_	_	_
20	very	_	_	RB	_	_	_	_	_
21	resistant	_	_	JJ	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	bacteria	_	_	NN	_	_	_	_	_
4	cells	_	_	NNS	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	biofilm	_	_	NN	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	more	_	_	RBR	_	_	_	_	_
9	resistant	_	_	JJ	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	toxic	_	_	JJ	_	_	_	_	_
12	substances	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	UV	_	_	NN	_	_	_	_	_
15	radiation	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	mechanical	_	_	JJ	_	_	_	_	_
18	damage	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	bacteriophages	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	or	_	_	CC	_	_	_	_	_
23	predators	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	more	_	_	RBR	_	_	_	_	_
5	resistant	_	_	JJ	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	immune	_	_	JJ	_	_	_	_	_
9	system	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	antibiotics	_	_	NNS	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	human	_	_	JJ	_	_	_	_	_
15	or	_	_	CC	_	_	_	_	_
16	animal	_	_	NN	_	_	_	_	_
17	body	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	surface	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	material	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	very	_	_	RB	_	_	_	_	_
8	quickly	_	_	RB	_	_	_	_	_
9	occupied	_	_	VBN	_	_	_	_	_
10	by	_	_	IN	_	_	_	_	_
11	bacteria	_	_	NN	_	_	_	_	_
12	because	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	host	_	_	NN	_	_	_	_	_
15	products	_	_	NNS	_	_	_	_	_
16	create	_	_	VBP	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	biofilm	_	_	NN	_	_	_	_	_
19	on	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	material	_	_	NN	_	_	_	_	_
22	that	_	_	WDT	_	_	_	_	_
23	helps	_	_	VBZ	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	bind	_	_	VB	_	_	_	_	_
26	the	_	_	DT	_	_	_	_	_
27	bacteria	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	process	_	_	NN	_	_	_	_	_
3	takes	_	_	VBZ	_	_	_	_	_
4	place	_	_	NN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	five	_	_	CD	_	_	_	_	_
7	stages	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	can	_	_	MD	_	_	_	_	_
11	be	_	_	VB	_	_	_	_	_
12	seen	_	_	VBN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	Figure	_	_	NN	_	_	_	_	_
15	3	_	_	CD	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	Biofilms	_	_	NNS	_	_	_	_	_
2	affect	_	_	VBP	_	_	_	_	_
3	many	_	_	JJ	_	_	_	_	_
4	medical	_	_	JJ	_	_	_	_	_
5	applications	_	_	NNS	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	a	_	_	DT	_	_	_	_	_
9	serious	_	_	JJ	_	_	_	_	_
10	medical	_	_	JJ	_	_	_	_	_
11	problem	_	_	NN	_	_	_	_	_
12	at	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	present	_	_	JJ	_	_	_	_	_
15	time	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	found	_	_	VBN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	example	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	catheters	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	stents	_	_	NNS	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	contact	_	_	NN	_	_	_	_	_
14	lenses	_	_	NNS	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	many	_	_	JJ	_	_	_	_	_
18	other	_	_	JJ	_	_	_	_	_
19	implants	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Biomaterials	_	_	NNS	_	_	_	_	_
2	at	_	_	IN	_	_	_	_	_
3	risk	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	attaching	_	_	VBG	_	_	_	_	_
6	bacteria	_	_	NNS	_	_	_	_	_
7	together	_	_	RB	_	_	_	_	_
8	with	_	_	IN	_	_	_	_	_
9	corresponding	_	_	VBG	_	_	_	_	_
10	body	_	_	NN	_	_	_	_	_
11	fluids	_	_	NNS	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	major	_	_	JJ	_	_	_	_	_
14	components	_	_	NNS	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	host	_	_	NN	_	_	_	_	_
18	products	_	_	NNS	_	_	_	_	_
19	for	_	_	IN	_	_	_	_	_
20	bacterial	_	_	JJ	_	_	_	_	_
21	growth	_	_	NN	_	_	_	_	_
22	are	_	_	VBP	_	_	_	_	_
23	classified	_	_	VBN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	Table	_	_	NNP	_	_	_	_	_
26	1	_	_	CD	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	biofilm	_	_	NN	_	_	_	_	_
3	’s	_	_	POS	_	_	_	_	_
4	high	_	_	JJ	_	_	_	_	_
5	resistance	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	antibacterial	_	_	JJ	_	_	_	_	_
8	agents	_	_	NNS	_	_	_	_	_
9	results	_	_	VBZ	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	great	_	_	JJ	_	_	_	_	_
13	risk	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	infection	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	therefore	_	_	RB	_	_	_	_	_
18	creates	_	_	VBZ	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	very	_	_	RB	_	_	_	_	_
21	hazardous	_	_	JJ	_	_	_	_	_
22	situation	_	_	NN	_	_	_	_	_
23	for	_	_	IN	_	_	_	_	_
24	patient	_	_	NN	_	_	_	_	_
25	health	_	_	NN	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Microbial	_	_	JJ	_	_	_	_	_
2	cells	_	_	NNS	_	_	_	_	_
3	that	_	_	WDT	_	_	_	_	_
4	live	_	_	VBP	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	biofilms	_	_	NNS	_	_	_	_	_
7	have	_	_	VBP	_	_	_	_	_
8	greater	_	_	JJR	_	_	_	_	_
9	resistance	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	antimicrobial	_	_	JJ	_	_	_	_	_
12	substances	_	_	NNS	_	_	_	_	_
13	than	_	_	IN	_	_	_	_	_
14	cells	_	_	NNS	_	_	_	_	_
15	that	_	_	WDT	_	_	_	_	_
16	live	_	_	VBP	_	_	_	_	_
17	alone	_	_	RB	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	planktonic	_	_	JJ	_	_	_	_	_
20	form	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Due	_	_	JJ	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	this	_	_	DT	_	_	_	_	_
4	resistance	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	treatment	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	biofilm	_	_	NN	_	_	_	_	_
10	infections	_	_	NNS	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	very	_	_	RB	_	_	_	_	_
13	difficult	_	_	JJ	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	Infected	_	_	JJ	_	_	_	_	_
2	implants	_	_	NNS	_	_	_	_	_
3	must	_	_	MD	_	_	_	_	_
4	be	_	_	VB	_	_	_	_	_
5	removed	_	_	VBN	_	_	_	_	_
6	from	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	patient	_	_	NN	_	_	_	_	_
9	’s	_	_	POS	_	_	_	_	_
10	body	_	_	NN	_	_	_	_	_
11	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	procedure	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	usually	_	_	RB	_	_	_	_	_
5	expensive	_	_	JJ	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	dangerous	_	_	JJ	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	because	_	_	IN	_	_	_	_	_
11	surgical	_	_	JJ	_	_	_	_	_
12	procedures	_	_	NNS	_	_	_	_	_
13	can	_	_	MD	_	_	_	_	_
14	cause	_	_	VB	_	_	_	_	_
15	other	_	_	JJ	_	_	_	_	_
16	complications	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Millions	_	_	NNS	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	implants	_	_	NNS	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	catheters	_	_	NNS	_	_	_	_	_
6	are	_	_	VBP	_	_	_	_	_
7	used	_	_	VBN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	treatment	_	_	NN	_	_	_	_	_
10	every	_	_	DT	_	_	_	_	_
11	year	_	_	NN	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_


1	Table	_	_	NN	_	_	_	_	_
2	2	_	_	CD	_	_	_	_	_
3	shows	_	_	VBZ	_	_	_	_	_
4	examples	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	implants	_	_	NNS	_	_	_	_	_
7	prone	_	_	JJ	_	_	_	_	_
8	to	_	_	TO	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	infections	_	_	NNS	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	biofilms	_	_	NNS	_	_	_	_	_
13	.	_	_	.	_	_	_	_	_


1	For	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	reason	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	new	_	_	JJ	_	_	_	_	_
6	materials	_	_	NNS	_	_	_	_	_
7	are	_	_	VBP	_	_	_	_	_
8	being	_	_	VBG	_	_	_	_	_
9	developed	_	_	VBN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	reduce	_	_	VB	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	risk	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	biofilm	_	_	NN	_	_	_	_	_
16	formation	_	_	NN	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	infection	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	materials	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	based	_	_	VBN	_	_	_	_	_
5	on	_	_	IN	_	_	_	_	_
6	polymer	_	_	NN	_	_	_	_	_
7	composites	_	_	NNS	_	_	_	_	_
8	or	_	_	CC	_	_	_	_	_
9	polymers	_	_	NNS	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	surfaces	_	_	NNS	_	_	_	_	_
12	modified	_	_	VBN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	an	_	_	DT	_	_	_	_	_
15	antimicrobial	_	_	JJ	_	_	_	_	_
16	agent	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	other	_	_	JJ	_	_	_	_	_
5	options	_	_	NNS	_	_	_	_	_
6	based	_	_	VBN	_	_	_	_	_
7	on	_	_	IN	_	_	_	_	_
8	physical	_	_	JJ	_	_	_	_	_
9	surface	_	_	NN	_	_	_	_	_
10	properties	_	_	NNS	_	_	_	_	_
11	such	_	_	JJ	_	_	_	_	_
12	as	_	_	IN	_	_	_	_	_
13	surface	_	_	NN	_	_	_	_	_
14	roughening	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	or	_	_	CC	_	_	_	_	_
17	vice	_	_	NN	_	_	_	_	_
18	versa	_	_	NN	_	_	_	_	_
19	smooth	_	_	JJ	_	_	_	_	_
20	surface	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	super	_	_	RB	_	_	_	_	_
23	hydrophobic	_	_	JJ	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	etc.	_	_	FW	_	_	_	_	_
26	should	_	_	MD	_	_	_	_	_
27	be	_	_	VB	_	_	_	_	_
28	considered	_	_	VBN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_

